Prolonged survival (17 years) in a patient with chronic myelogenous leukemia after therapy for Hodgkin's disease

• Published in: Leukemia & lymphoma Vol. 16; no. 1-2; p. 177
• Main Authors: Salvagno, L, Sorarú, M, Leszl, A, Koussis, H, De Franchis, G, Fiorentino, M V
• Format: Journal Article
• Language: English
• Published: United States 1994
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Combined Modality Therapy; Hodgkin Disease - drug therapy; Hodgkin Disease - genetics; Hodgkin Disease - radiotherapy; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - etiology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Male; Neoplasms, Second Primary - etiology; Neoplasms, Second Primary - genetics; Prognosis; Radiotherapy - adverse effects
• ISSN: 1042-8194
• DOI: 10.3109/10428199409114156

A case of secondary chronic myelogenous leukemia after successful therapy for Hodgkin's disease is reported. The patient was diagnosed as having stage IIIA Hodgkin's disease, at the age of 33. He underwent staging laparosplenectomy and was treated with radiotherapy plus chemotherapy. Forty three months after the diagnosis of Hodgkin's disease, a Philadelphia-positive chronic myelogenous leukemia developed. It required periodic chemotherapy and each time a remission, lasting several months (up to 14 months), was obtained. The disease had an unusually prolonged clinical course, and the blast crisis, of lymphoid type, occurred only 17 years later.